CEL-SCI Corporation to Present at H.C. Wainwright 22nd Annual Global Investment Conference

On September 11, 2020 CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, reported that it will be presenting at the H.C. Wainwright 22nd Annual Global Investment Conference (Press release, Cel-Sci, SEP 11, 2020, View Source [SID1234565030]). The virtual conference will be held on September 14-16, 2020. Geert Kersten, Chief Executive Officer of CEL-SCI, will present on Monday, September 14 at 1:30 p.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

For those who wish to listen to the live webcast, please use the following link View Source The webcast will be archived on CEL-SCI’s investor relations website, View Source for 90 days following the live presentation.

Use the contact form at the top or bottom of this page to book a free demo to 1stOncology™, an all inclusive cancer drug development intelligence platform from BioSeeker. The platform provides value in oncology for you in areas such as:

Target scouting
Indication selection & expansion
Combinatorial drug settings
Drug repositioning
First in class analysis
Compound cross over analysis
Competitive analysis
Pathway analysis

and much more...

1stOncology is recognized as a
Top 10 Global Pharma Analytic Provider

Continue your journey with 1stOncology by accessing our Free Leading Cancer Conference Whitepapers, signing up for our Free Weekly Newsletter and requesting a Free Demo to see how we can help you be 1st in Oncology!